Every 8-K that Twist Bioscience (TWST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TWST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TWST filings page.
Twist Bioscience Corporation (TWST) reports that, under a Registration Rights Agreement dated February 11, 2026 with Invenra Inc., it is registering the resale of shares issuable to Invenra under a related Stock Purchase Agreement dated the same day. The company is filing a prospectus supplement to cover these resale shares. An opinion of Orrick, Herrington & Sutcliffe LLP regarding the validity of the shares is included as Exhibit 5.1.
Twist Bioscience Corporation (TWST) reported that Anthropic, PBC published a blog post describing results from a multi-arm protein design campaign against 15 targets using its Claude Opus 4.8 and Mythos Preview AI models. Anthropic selected Twist Bioscience as one of its independent evaluators to rapidly manufacture these AI-designed proteins at scale and test them for binding.
The disclosure is made under Regulation FD and is furnished, not filed, meaning it is not automatically incorporated into Twist Bioscience’s Securities Act filings unless specifically referenced there.
Twist Bioscience Corporation entered into an underwriting agreement for a primary public offering of 3,125,000 shares of common stock at $96.00 per share, with underwriters granted a 30-day option for up to 468,750 additional shares, which has been exercised in full.
The transaction, conducted under Twist’s automatic shelf registration, is expected to generate approximately $327.1 million in net proceeds after underwriting discounts and expenses, with closing anticipated on August 6, 2026, subject to customary conditions. Twist plans to use the proceeds, together with existing cash, to fund research and development, expand manufacturing capacity, support product offerings, and for working capital and other general corporate purposes.
Twist Bioscience reported record fiscal Q3 2026 revenue of $118.4 million, up 23% year over year and marking its 14th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose to $56.6 million and NGS Applications to $61.8 million, with both segments growing sequentially. Gross margin improved to 52.8% from 51.6% in the prior quarter.
The company posted a net loss of $35.1 million, or $0.56 per diluted share, versus prior-year net income of $20.4 million that included a $48.8 million gain from the Atlas Data Storage spin-out. Adjusted EBITDA was $(11.3) million and cash, cash equivalents and short-term investments totaled about $167 million as of June 30, 2026. Management raised full-year 2026 revenue guidance to $456–$457 million, approximately 21% growth, and expects Q4 revenue of $123–$124 million with adjusted EBITDA breakeven.
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Twist Bioscience Corporation entered into stock purchase agreements with Invenra Inc. and two of Invenra’s investors. Twist will issue up to 632,328 shares of common stock. Up to 324,558 shares plus $5 million in cash will be provided to Invenra in exchange for a license agreement and certain technology. Twist will also issue up to 307,770 shares to two Invenra investors in exchange for preferred stock, giving Twist approximately a 6% ownership stake in Invenra. Twist gains the right to designate one director to Invenra’s board, whose members, including the Twist designee, may approve two additional directors. The company simultaneously granted registration rights and is filing a prospectus supplement to register the resale of these shares.
Twist Bioscience Corporation held its 2026 Annual Meeting of Stockholders, with strong participation from holders of 56,260,506 common shares, representing about 91.81% of shares eligible to vote. This high turnout indicates that most stockholders were represented, either in person or by proxy.
Stockholders elected three Class II directors to three-year terms: Keith Crandell, Jan Johannessen, and Trynka Shineman Blake. Blake received 50,217,493 votes for and 88,210 votes withheld, while Crandell and Johannessen each also secured substantial majorities, ensuring continuity on the board.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,430,673 votes for, 11,842,367 against, and 32,663 abstentions, along with 5,954,803 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions.
Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.
Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025. The company announced these early revenue figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. Twist notes that these revenue expectations are preliminary and may change after it completes its internal control, review, and audit procedures, so the final numbers in its quarterly financial statements could differ materially. The company also states that this information is being furnished, not filed, which limits how it is treated under securities law.
Twist Bioscience Corporation furnished an 8-K to announce financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2025. The company issued a press release on November 14, 2025, and attached it as Exhibit 99.1 titled “Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results.”
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated. Twist’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.